An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)

Inclusion Criteria: Please Note: In this trial an Indian female participant is defined as a woman 1) with native Indian parents, and 2) who is also in possession of an Indian identification card. * Indian woman with an indication for COS and IVF/ICSI, but has not yet undergone IVF/ICSI. * Body mass index (BMI) of 18.0 to 32.0 kg/m2 * Regular spontaneous menstrual cycle (ie, a menstrual schedule that consistently occurs within a range of 24 to 35 days) * Access to available ejaculatory sperm. Use of donated and/or cryopreserved sperm is allowed, however sperm obtained via surgical sperm retrieval is not allowed. * Results documented as 'within normal limits' from clinical laboratory tests (ie, complete blood count \[CBC\], blood chemistries, and urinalysis). * Normal cervical smear result obtained within 12 months prior to study enrollment, otherwise test will be performed during screening. * Able to adhere to dose and study visit schedules Exclusion Criteria: \- Has a recent (ie, within 3 years prior to enrollment in study) history of/or any active endocrine abnormality, treated or untreated. * Contraindicated use of gonadotropins * History of ovarian hyper-responsiveness * History of/or current polycystic ovary syndrome (PCOS) * Has less than 2 ovaries or has any other ovarian abnormality, including endometrioma (greater than 10 mm in size), and/or has unilateral or bilateral hydrosalpinx and/or intrauterine fibroids (5 cm in size or greater), confirmed by an ultrasound scan. * Has any clinically relevant pathology that may impair embryo implantation or continuation of pregnancy. * Experienced more than three unsuccessful COS cycles for IVF/ICSI since the last established ongoing pregnancy, if applicable. * History of non- or low ovarian response to FSH and/or Menopausal Gonadotropin (hMG) treatment. * History of recurrent miscarriage (ie, 3 or more) * Positive test results for Human Immunodeficiency Virus (HIV) or Hepatitis B * Recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease, any of which required or requires treatment. * Smokes or recently stopped smoking (ie, within 3 months of study enrollment) * History of/or active alcohol and/or drug abuse (ie, within 12 months prior to study enrollment). * Previous use of corifollitropin alfa * Use of hormonal agents known to affect ovulation or any drug/agent considered to be teratogenic * Use of any experimental drug within 3 months prior to study enrollment or participation in another clinical study, other than one that is survey-questionnaire based.